Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices

This analysis evaluated the efficacy and safety of bevacizumab as monotherapy and with irinotecan for recurrent glioblastoma in community-based practices. Adult patients with bevacizumab-naive, recurrent glioblastoma initiating second-line treatment (July 2006–June 2010) were identified using McKess...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Clara, Ravelo, Arliene, Yu, Elaine, Dhanda, Rahul, Schnadig, Ian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436682/
https://www.ncbi.nlm.nih.gov/pubmed/25773061
http://dx.doi.org/10.1007/s11060-015-1752-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436682/
https://www.ncbi.nlm.nih.gov/pubmed/25773061
http://dx.doi.org/10.1007/s11060-015-1752-y

Ejemplares similares